Last reviewed · How we verify
Synbiotic 2000
Synbiotic 2000 is a prebiotic and probiotic combination that modulates the gut microbiota to support immune function and gastrointestinal health.
Synbiotic 2000 is a prebiotic and probiotic combination that modulates the gut microbiota to support immune function and gastrointestinal health. Used for Support of gastrointestinal health and microbiota balance, Immune system support.
At a glance
| Generic name | Synbiotic 2000 |
|---|---|
| Sponsor | Beth Israel Medical Center |
| Drug class | Synbiotic (prebiotic + probiotic combination) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
The product combines inulin (prebiotic fiber) and four probiotic bacterial strains to promote beneficial bacterial growth and restore healthy microbiota composition. This modulation of the gut microbiome is intended to enhance intestinal barrier function, reduce pathogenic bacterial overgrowth, and support systemic immune responses through improved gut-associated lymphoid tissue (GALT) function.
Approved indications
- Support of gastrointestinal health and microbiota balance
- Immune system support
Common side effects
- Gastrointestinal bloating or gas
- Mild digestive discomfort
Key clinical trials
- Open Label Randomized Clinical Study to Promote a Healthy Lifestyle in Medical Students (NA)
- Pilot Trial of a Synbiotic in HIV+ Patients (NA)
- The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synbiotic 2000 CI brief — competitive landscape report
- Synbiotic 2000 updates RSS · CI watch RSS
- Beth Israel Medical Center portfolio CI